Salicylic Acid (BHA): Follicular Exfoliation, pH and Formulation Science
Micellar Cosmetics™ Ingredient Library · Skin Clarity & Formulation Science
Salicylic Acid (BHA): Follicular Exfoliation, pH and Formulation Science
INCI: Salicylic Acid · Family: Aromatic hydroxy acid, often marketed as BHA · Properties: Weak organic acid; limited intrinsic water solubility; formulation- and pH-dependent ionisation
Salicylic acid is widely used in clarifying skincare because it influences the shedding of corneocytes and the appearance of congestion in pores. It is particularly relevant to the follicular environment associated with blackheads and whiteheads. But its performance depends on more than the ingredient percentage: pH, dissolved state, vehicle composition, stability, contact time and tolerance must all be considered.
1. What is Salicylic Acid?
Salicylic acid is 2-hydroxybenzoic acid, a small aromatic organic acid. Although its hydroxyl and carboxylic acid groups are not arranged like those of classical aliphatic beta-hydroxy acids, cosmetic products commonly describe salicylic acid as a beta-hydroxy acid (BHA). It is not the same substance as aspirin (acetylsalicylic acid). [1]
Salicylic acid is used in skin-care products for exfoliation, clarifying and smoothing functions. At appropriate application conditions, it can influence the cohesion and shedding of cells at the outermost skin surface and near follicular openings. It should not be presented as simply dissolving dirt or physically washing sebum from pores.
2. What happens inside a blemish-prone follicle?
Acne biology is centred on the pilosebaceous unit: a hair follicle associated with a sebaceous gland. The classical description involves abnormal follicular keratinisation, changes in sebum production and composition, the local biology of Cutibacterium acnes, and inflammation. These processes interact; acne is not caused simply by poor hygiene. [2, 3]
When corneocytes accumulate at the follicular opening, a microcomedo can develop, potentially becoming an open comedo (blackhead) or closed comedo (whitehead). The black colour of a blackhead should not be described as accumulated dirt. C. acnes is part of the normal skin microbiota; disease-associated changes relate to strains, microenvironment and host immune responses, not the mere presence of the organism. [2]
Follicular exfoliation is therefore biologically relevant, but it addresses only part of a multifactorial condition.
3. How does salicylic acid work?
Salicylic acid is commonly described as comedolytic or desmolytic, reflecting its ability under certain conditions to weaken the cohesion of superficial corneocytes and encourage shedding. Its aromatic structure and partitioning characteristics are relevant to interactions with lipid-containing follicular environments. [3, 4]
The extent of the effect depends on the formulation and application conditions. It is inaccurate to infer that every salicylic-acid product penetrates deeply into all follicles simply because the ingredient is often described as oil-soluble or follicle-targeting.
Inflammation is also involved in acne biology, but topical salicylic acid should not be portrayed as eliminating all inflammatory mechanisms or directly treating severe acne without appropriate clinical evidence.
4. What does the human evidence show?
The American Academy of Dermatology's 2024 acne-treatment guideline provides a conditional recommendation for topical salicylic acid. This recommendation is weaker than its strong recommendations for some established acne medications. The guideline bases its salicylic-acid recommendation on a limited randomised trial evidence base; its findings should not be generalised to all cosmetic leave-on vehicles. [3]
The 2025 international dermocosmetics consensus found that suitably designed skincare may benefit people with acne-prone skin or support tolerability alongside standard therapy, while noting that the overall quality of supporting research was low to moderate and that evidence was insufficient to attribute benefits to every specific ingredient. [5]
Evidence interpretation: Ingredient studies and medical acne-treatment guidelines offer scientific context. They do not prove that an individual cosmetic formula prevents or cures acne. For a specific product, claims require evidence appropriate to its composition, use and market classification.
5. Formulation chemistry: pH, ionisation and physical state
Salicylic acid has a carboxyl-group pKa of approximately 2.97. In a simple aqueous model, its unionised-to-ionised ratio changes with pH: increasing pH produces a larger salicylate fraction, while lowering pH favours unionised salicylic acid. [1]
This matters because acid ionisation affects aqueous solubility, lipid partitioning and formulation behaviour. However, an idealised Henderson–Hasselbalch calculation alone cannot predict delivery or biological activity within a multicomponent microemulsion or on skin. Solvents, surfactants, interfaces, activity coefficients, phase composition and changes after application all matter.
The practical formulation challenge is to maintain sufficient dissolved salicylic acid without unacceptable crystallisation, phase instability or irritation. Clarity by itself does not show where the ingredient resides or how much becomes available at the skin surface.
- Solubilisation: ensure the active is incorporated in a physically compatible form, not merely temporarily dispersed.
- pH and buffering: account for acid speciation, desired skin compatibility and the effects of other formulation ingredients.
- Vehicle composition: evaluate water, lipophilic components, cosurfactants, surfactants and electrolyte load.
- Stability: inspect crystallisation, clarity, phase separation, pH drift and active assay over appropriate storage conditions.
- Use conditions: assess wash-off versus leave-on exposure, frequency, co-applied products and sensitivity.
Scientific comparisons should therefore describe the finished formulation rather than assume that two products with the same nominal salicylic-acid concentration are equivalent.
6. Skin-barrier comfort and sensible use
Excessive cleansing, abrasive scrubs or stacking strong exfoliants can irritate skin, including blemish-prone skin. Dermatology guidance supports gentle cleansing, avoidance of unnecessary abrasion and appropriate moisturisation. [6, 7]
Dryness, stinging, flaking or redness may occur with salicylic-acid products, depending on the strength of the formulation, frequency and skin sensitivity. Consumers should follow product directions, avoid irritated or broken skin where appropriate, and reduce use if persistent irritation develops.
Persistent, widespread, painful, nodular or scarring acne requires medical advice. Cosmetic products should not be relied upon to treat a medical condition.
In Singapore, the HSA definition of a cosmetic product excludes products intended for treatment, such as acne-treatment creams. Educational information about acne must remain distinct from unsubstantiated therapeutic claims for cosmetics. [8]
7. Related ingredients, formulations and learning
Complementary skin-conditioning ingredients: Sodium Ascorbyl Phosphate (SAP) has preliminary blemish-related and antioxidant research, while Niacinamide is used for barrier and skin-conditioning functions. These act through different mechanisms from exfoliation. A complementary ingredient list is a formulation rationale, not proof of additive clinical efficacy.
Green Micellar™ approach: Micellar Cosmetics™ develops microemulsion-native systems intended to accommodate selected hydrophilic and lipophilic actives while allowing different product formats. For salicylic acid, relevant measurements include compatibility, clarity, pH, phase stability, analytical active retention, release and skin tolerance. Small dispersed-domain dimensions alone do not establish follicular targeting or clinical outcomes.
Consumer education: See the Ingredient Library, the Learning Hub Journal and the DermaClear™ BHA Clarifying Serum product guide for product-use information. A dedicated acne and blemish-prone skin Journal article is planned for 29 November 2026.
8. Scientific and regulatory references
- National Center for Biotechnology Information. PubChem: Salicylic Acid, CID 338. Physical chemistry, acid dissociation data. PubChem.
- Acne: epidemiology, risk factors, pathogenesis, management and cutting-edge research. Signal Transduction and Targeted Therapy (2026). Full review.
- Reynolds RV, et al. (2024). Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 90:1006.e1–1006.e30. PMID 38300170 · DOI.
- Del Rosso JQ, et al. (2024). The primary role of sebum in the pathophysiology of acne vulgaris and its therapeutic relevance in acne management. J Dermatolog Treat. PMID 38146664.
- Thiboutot D, et al. (2025; online 2024). International expert consensus recommendations for the use of dermocosmetics in acne. J Eur Acad Dermatol Venereol 39:952–966. PMID 38877766 · DOI.
- American Academy of Dermatology. Face washing 101. Dermatologist advice.
- American Academy of Dermatology. 10 skin care habits that can worsen acne. Dermatologist advice.
- Singapore Health Sciences Authority. Regulatory overview of cosmetic products. Updated November 2026. HSA guidance.
- Klock J, et al. (2005). Sodium ascorbyl phosphate shows in vitro and in vivo efficacy in the prevention and treatment of acne vulgaris. Int J Cosmet Sci 27:171–176. PMID 18492184. Study designs and vehicles limit product extrapolation.
Scientific evidence note: This Ingredient Library profile discusses the chemistry of salicylic acid, published research and cosmetic formulation principles. Results from clinical studies or other delivery vehicles do not establish identical performance for Micellar Cosmetics™ products. Educational information only; not medical advice or a claim to treat acne.